Example of Therapeutics and Clinical Risk Management format
Recent searches

Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format Example of Therapeutics and Clinical Risk Management format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Therapeutics and Clinical Risk Management — Template for authors

Publisher: Dove Medical Press
Categories Rank Trend in last 3 yrs
Safety Research #15 of 88 down down by 8 ranks
Pharmacology, Toxicology and Pharmaceutics (all) #15 of 67 down down by 2 ranks
Pharmacology (medical) #100 of 246 down down by 1 rank
Chemical Health and Safety #5 of 11 down down by 2 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 727 Published Papers | 2768 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 19/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Hindawi

Quality:  
High
CiteRatio: 6.4
SJR: 0.822
SNIP: 2.064
open access Open Access
recommended Recommended

Taylor and Francis

Quality:  
High
CiteRatio: 7.2
SJR: 1.023
SNIP: 1.448
open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 6.4
SJR: 1.187
SNIP: 1.192
open access Open Access
recommended Recommended

Taylor and Francis

Quality:  
High
CiteRatio: 4.0
SJR: 0.545
SNIP: 1.328

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

1.888

4% from 2018

Impact factor for Therapeutics and Clinical Risk Management from 2016 - 2019
Year Value
2019 1.888
2018 1.824
2017 1.995
2016 2.2
graph view Graph view
table view Table view

3.8

19% from 2019

CiteRatio for Therapeutics and Clinical Risk Management from 2016 - 2020
Year Value
2020 3.8
2019 3.2
2018 3.3
2017 3.7
2016 2.8
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 4% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 19% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

0.719

19% from 2019

SJR for Therapeutics and Clinical Risk Management from 2016 - 2020
Year Value
2020 0.719
2019 0.604
2018 0.725
2017 0.748
2016 0.765
graph view Graph view
table view Table view

1.081

20% from 2019

SNIP for Therapeutics and Clinical Risk Management from 2016 - 2020
Year Value
2020 1.081
2019 0.904
2018 0.964
2017 1.037
2016 0.986
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 19% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 20% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Therapeutics and Clinical Risk Management

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Dove Medical Press

Therapeutics and Clinical Risk Management

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sust...... Read More

Safety Research

General Pharmacology, Toxicology and Pharmaceutics

General Medicine

Chemical Health and Safety

Pharmacology (medical)

Social Sciences

i
Last updated on
19 Jul 2020
i
ISSN
1176-6336
i
Impact Factor
High - 1.16
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Blue faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
unsrt
i
Citation Type
Numbered
[25]
i
Bibliography Example
C. W. J. Beenakker. Specular andreev reflection in graphene. Phys. Rev. Lett., 97(6):067007, 2006.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.2147/TCRM.S1458
Factors affecting therapeutic compliance: A review from the patient's perspective.
Jing Jin1, Grant E. Sklar, Vernon Min Sen Oh, Shu-Chuen Li2

Abstract:

Objective To explore and evaluate the most common factors causing therapeutic non-compliance.
View PDF
979 Citations
open accessOpen access Journal Article
The challenge of patient adherence

Abstract:

Quality healthcare outcomes depend upon patients' adherence to recommended treatment regimens. Patient nonadherence can be a pervasive threat to health and wellbeing and carry an appreciable economic burden as well. In some disease conditions, more than 40% of patients sustain significant risks by misunderstanding, forgetting... Quality healthcare outcomes depend upon patients' adherence to recommended treatment regimens. Patient nonadherence can be a pervasive threat to health and wellbeing and carry an appreciable economic burden as well. In some disease conditions, more than 40% of patients sustain significant risks by misunderstanding, forgetting, or ignoring healthcare advice. While no single intervention strategy can improve the adherence of all patients, decades of research studies agree that successful attempts to improve patient adherence depend upon a set of key factors. These include realistic assessment of patients' knowledge and understanding of the regimen, clear and effective communication between health professionals and their patients, and the nurturance of trust in the therapeutic relationship. Patients must be given the opportunity to tell the story of their unique illness experiences. Knowing the patient as a person allows the health professional to understand elements that are crucial to the patient's adherence: beliefs, attitudes, subjective norms, cultural context, social supports, and emotional health challenges, particularly depression. Physician–patient partnerships are essential when choosing amongst various therapeutic options to maximize adherence. Mutual collaboration fosters greater patient satisfaction, reduces the risks of nonadherence, and improves patients' healthcare outcomes. read more read less

Topics:

Patient satisfaction (56%)56% related to the paper, Health care (52%)52% related to the paper, Therapeutic relationship (52%)52% related to the paper
790 Citations
open accessOpen access Journal Article DOI: 10.2147/TCRM.S40160
Epidemiology and risk factors for invasive candidiasis
Nur Yapar1

Abstract:

The number of immunosuppressive patients has increased significantly in recent years. These patients are at risk for opportunistic infections, especially fungal infections. Candidiasis is one of the most frequent fungal infections determined in these immunosuppressive patients and its epidemiology has changed over the last tw... The number of immunosuppressive patients has increased significantly in recent years. These patients are at risk for opportunistic infections, especially fungal infections. Candidiasis is one of the most frequent fungal infections determined in these immunosuppressive patients and its epidemiology has changed over the last two decades. Recently, new antifungal agents and new therapy strategies such as antifungal prophylaxis, secondary prophylaxis, and preemptive therapy have come into use. These changes resulted in the alteration of Candida species causing invasive infections. The incidence of Candida albicans was decreased in many countries, espe- cially among patients with immunosuppressive disorders, while the incidence of species other than C. albicans was increased. In this review, incidence, risk factors, and species distribution of invasive candidiasis are discussed. read more read less

Topics:

Candida albicans (63%)63% related to the paper, Incidence (epidemiology) (51%)51% related to the paper
View PDF
417 Citations
open accessOpen access Journal Article DOI: 10.2147/TCRM.S3025
The benefits and risks of testosterone replacement therapy: a review
Nazem Bassil, Saad Alkaade, John E. Morley1

Abstract:

Increased longevity and population aging will increase the number of men with late onset hypogonadism. It is a common condition, but often underdiagnosed and undertreated. The indication of testosterone-replacement therapy (TRT) treatment requires the presence of low testosterone level, and symptoms and signs of hypogonadism.... Increased longevity and population aging will increase the number of men with late onset hypogonadism. It is a common condition, but often underdiagnosed and undertreated. The indication of testosterone-replacement therapy (TRT) treatment requires the presence of low testosterone level, and symptoms and signs of hypogonadism. Although controversy remains regarding indications for testosterone supplementation in aging men due to lack of large-scale, long-term studies assessing the benefits and risks of testosterone-replacement therapy in men, reports indicate that TRT may produce a wide range of benefits for men with hypogonadism that include improvement in libido and sexual function, bone density, muscle mass, body composition, mood, erythropoiesis, cognition, quality of life and cardiovascular disease. Perhaps the most controversial area is the issue of risk, especially possible stimulation of prostate cancer by testosterone, even though no evidence to support this risk exists. Other possible risks include worsening symptoms of benign prostatic hypertrophy, liver toxicity, hyperviscosity, erythrocytosis, worsening untreated sleep apnea or severe heart failure. Despite this controversy, testosterone supplementation in the United States has increased substantially over the past several years. The physician should discuss with the patient the potential benefits and risks of TRT. The purpose of this review is to discuss what is known and not known regarding the benefits and risks of TRT. read more read less

Topics:

Testosterone (patch) (55%)55% related to the paper, Libido (51%)51% related to the paper
View PDF
281 Citations
open accessOpen access Journal Article DOI: 10.2147/TCRM.S84210
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.

Abstract:

Despite the discovery and application of many parenteral (unfractionated and low-molecular-weight heparins) and oral anticoagulant vitamin K antagonist (VKA) drugs, the prevention and treatment of venous and arterial thrombotic phenomena remain major medical challenges. Furthermore, VKAs are the only oral anticoagulants used ... Despite the discovery and application of many parenteral (unfractionated and low-molecular-weight heparins) and oral anticoagulant vitamin K antagonist (VKA) drugs, the prevention and treatment of venous and arterial thrombotic phenomena remain major medical challenges. Furthermore, VKAs are the only oral anticoagulants used during the past 60 years. The main objective of this study is to present recent data on non-vitamin K antagonist oral anticoagulants (NOACs) and to analyze their advantages and disadvantages compared with those of VKAs based on a large number of recent studies. NOACs are novel direct-acting medications that are selective for one specific coagulation factor, either thrombin (IIa) or activated factor X (Xa). Several NOACs, such as dabigatran (a direct inhibitor of FIIa) and rivaroxaban, apixaban and edoxaban (direct inhibitors of factor Xa), have been used for at least 5 years but possibly 10 years. Unlike traditional VKAs, which prevent the coagulation process by suppressing the synthesis of vitamin K-dependent factors, NOACs directly inhibit key proteases (factors IIa and Xa). The important indications of these drugs are the prevention and treatment of deep vein thrombosis and pulmonary embolisms, and the prevention of atherothrombotic events in the heart and brain of patients with acute coronary syndrome and atrial fibrillation. They are not fixed, and dose-various strengths are available. Most studies have reported that more advantages than disadvantages for NOACs when compared with VKAs, with the most important advantages of NOACs including safety issues (ie, a lower incidence of major bleeding), convenience of use, minor drug and food interactions, a wide therapeutic window, and no need for laboratory monitoring. Nonetheless, there are some conditions for which VKAs remain the drug of choice. Based on the available data, we can conclude that NOACs have greater advantages and fewer disadvantages compared with VKAs. New studies are required to further assess the efficacy of NOACs. read more read less

Topics:

Rivaroxaban (58%)58% related to the paper, Edoxaban (57%)57% related to the paper, Apixaban (56%)56% related to the paper, Vitamin K antagonist (53%)53% related to the paper, Dabigatran (51%)51% related to the paper
View PDF
243 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Therapeutics and Clinical Risk Management.

It automatically formats your research paper to Dove Medical Press formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Therapeutics and Clinical Risk Management format uses unsrt citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Therapeutics and Clinical Risk Management in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Therapeutics and Clinical Risk Management guidelines and auto format it.

2. Do you follow the Therapeutics and Clinical Risk Management guidelines?

Yes, the template is compliant with the Therapeutics and Clinical Risk Management guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Therapeutics and Clinical Risk Management?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Therapeutics and Clinical Risk Management citation style.

4. Can I use the Therapeutics and Clinical Risk Management templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Therapeutics and Clinical Risk Management.

5. Can I use a manuscript in Therapeutics and Clinical Risk Management that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Therapeutics and Clinical Risk Management that you can download at the end.

6. How long does it usually take you to format my papers in Therapeutics and Clinical Risk Management?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Therapeutics and Clinical Risk Management.

7. Where can I find the template for the Therapeutics and Clinical Risk Management?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Therapeutics and Clinical Risk Management's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Therapeutics and Clinical Risk Management's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Therapeutics and Clinical Risk Management an online tool or is there a desktop version?

SciSpace's Therapeutics and Clinical Risk Management is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Therapeutics and Clinical Risk Management?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Therapeutics and Clinical Risk Management?”

11. What is the output that I would get after using Therapeutics and Clinical Risk Management?

After writing your paper autoformatting in Therapeutics and Clinical Risk Management, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Therapeutics and Clinical Risk Management's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Therapeutics and Clinical Risk Management?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Therapeutics and Clinical Risk Management. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Therapeutics and Clinical Risk Management?

The 5 most common citation types in order of usage for Therapeutics and Clinical Risk Management are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Therapeutics and Clinical Risk Management?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Therapeutics and Clinical Risk Management's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Therapeutics and Clinical Risk Management in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Therapeutics and Clinical Risk Management Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Therapeutics and Clinical Risk Management formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template